Dengue Vaccine Reaches Phase III Clinical Trail, But Some Experts Question Efficacy

Deutsche Welle: Experts see flaws in promising dengue fever vaccine candidate
“The most advanced vaccine candidate against dengue fever could prevent many deaths, its developers say. But some experts warn that the substance could even make things worse rather than effectively treat it. … Sanofi Pasteur’s vaccine protects quite well against serotypes 3 and 4 with an efficacy of 75 percent. Protection against serotype 1 is 50 percent while against serotype 2 it is only 35 percent effective…” (Osterath, 7/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.